What the July 2026 PCAC Votes Did and Did Not Change

What the committee decided

At its meeting on 23 and 24 July 2026, the Pharmacy Compounding Advisory Committee recommended adding six peptides to the Section 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, each in free base and acetate form. It voted against recommending Emideltide, also referred to as DSIP. Seven substances were considered in total. The committee is advisory, and its votes did not change the legal status of any of them.

The vote was close, and the agency staff disagreed

BPC-157, KPV and TB-500 each passed by eight votes to six with one abstention. MOTS-c passed by seven to five with two abstentions. These are narrow margins on a divided committee. More consequential: the scientific staff at the agency had recommended against including all seven substances, citing the available information on characterisation, safety and effectiveness. The committee reached the opposite conclusion. That divergence matters, because the agency is not obliged to follow the advice of its own committee.

What the 503A Bulks List actually governs

Section 503A of the Federal Food, Drug, and Cosmetic Act governs what a state-licensed pharmacy may use when compounding a medication for an individual patient. The list, codified at 21 CFR 216.23, names bulk drug substances eligible for that use. A substance on the list has not been through premarket review, and compounded preparations do not undergo the evaluation that an approved drug application requires. The list answers a narrow question: whether a compounding pharmacy may work with a given raw substance at all.

A recommendation is not a rule

Formal addition to the list requires notice-and-comment rulemaking: a proposed rule, a public comment period, review of the comments received, and a final rule. None of that has concluded. A pharmacy compounding these substances on the strength of the July votes would be acting ahead of any rule. Some observers expect informal enforcement discretion in the interim, but discretion is not authorisation, it is not published, and it can be withdrawn without notice.

Four states that are not the same thing

Coverage of these developments routinely collapses four distinct administrative states into a single claim. Removal from Category 2, which identifies substances flagged for significant safety risk, is not placement in Category 1. Neither is addition to the 503A Bulks List. And none of the three amounts to approval of a drug by the agency. The April sequence compounded the confusion: on 15 April 2026 the agency announced, with a Federal Register notice the following day, that twelve peptides would come off the Category 2 list effective 23 April 2026. The original nominators had withdrawn their nominations that same month, after which the July meeting was scheduled and docket FDA-2025-N-6895 opened for written comment.

What changed for laboratory research material

Nothing. The compounding pathway governs pharmacies preparing medications for individual patients. Material supplied for laboratory research sits outside that pathway, and the July votes altered neither what a research supplier may offer nor how it must be labelled. What did change is the volume of public confusion. A buyer evaluating suppliers in late 2026 will encounter claims that these six peptides are now approved, legal or cleared. None of those characterisations is accurate, and a supplier making them is describing a regulatory position that does not exist.

What to verify instead

Regulatory status is not a proxy for material quality, and none of these votes says anything about the contents of a particular vial. The questions that bear on the material are unchanged. Is there a certificate tied to this specific lot rather than one representative document reused across batches? Which assays were performed, and which were not? Does the measured content correspond to the label claim? Does the lot number on the certificate match the number printed on the vial? A document that cannot survive those four questions is decorative regardless of what any committee recommended.

The six substances, and the certificates behind them

All six peptides the committee recommended appear in our catalog, each with lot-specific analytical results published rather than summarised: BPC-157, KPV, TB-500, MOTS-C, Epitalon and Semax. The certificates record what an independent laboratory measured on a specific batch: purity by HPLC-UV, identity by LC-MS, and endotoxin by LAL where that assay was performed. None of that speaks to regulatory status, and it is not intended to. It answers the separate question of what a given vial contains, which no committee vote addresses.

• BPC-157 — published lots
• KPV — published lots
• TB-500 — published lots
• MOTS-C — published lots
• Epitalon — published lots
• Semax — published lots